{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T11:07:43Z","timestamp":1793444863884,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2009,3,19]],"date-time":"2009-03-19T00:00:00Z","timestamp":1237420800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Immunol"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1038\/ni.1701","type":"journal-article","created":{"date-parts":[[2009,3,19]],"date-time":"2009-03-19T11:17:12Z","timestamp":1237461432000},"page":"356-360","source":"Crossref","is-referenced-by-count":216,"title":["Selectivity and therapeutic inhibition of kinases: to be or not to be?"],"prefix":"10.1038","volume":"10","author":[{"given":"Kamran","family":"Ghoreschi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arian","family":"Laurence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J","family":"O'Shea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,3,19]]},"reference":[{"key":"BFni1701_CR1","first-page":"1511","volume":"25","author":"EH Fischer","year":"1966","unstructured":"Fischer, E.H. & Krebs, E.G. Relationship of structure to function of muscle phosphorylase. Fed. Proc. 25, 1511\u20131520 (1966).","journal-title":"Fed. Proc."},{"key":"BFni1701_CR2","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1126\/science.1058040","volume":"291","author":"JC Venter","year":"2001","unstructured":"Venter, J.C. et al. The sequence of the human genome. Science 291, 1304\u20131351 (2001).","journal-title":"Science"},{"key":"BFni1701_CR3","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1126\/science.1075762","volume":"298","author":"G Manning","year":"2002","unstructured":"Manning, G., Whyte, D.B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 298, 1912\u20131934 (2002).","journal-title":"Science"},{"key":"BFni1701_CR4","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/0092-8674(87)90509-5","volume":"50","author":"T Hunter","year":"1987","unstructured":"Hunter, T. A thousand and one protein kinases. Cell 50, 823\u2013829 (1987).","journal-title":"Cell"},{"key":"BFni1701_CR5","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/373477a0","volume":"373","author":"T Pawson","year":"1995","unstructured":"Pawson, T. Protein-tyrosine kinases. Getting down to specifics. Nature 373, 477\u2013478 (1995).","journal-title":"Nature"},{"key":"BFni1701_CR6","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/373573a0","volume":"373","author":"T Pawson","year":"1995","unstructured":"Pawson, T. Protein modules and signalling networks. Nature 373, 573\u2013580 (1995).","journal-title":"Nature"},{"key":"BFni1701_CR7","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","volume":"289","author":"T Schindler","year":"2000","unstructured":"Schindler, T. et al. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 289, 1938\u20131942 (2000).","journal-title":"Science"},{"key":"BFni1701_CR8","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1126\/science.2406902","volume":"247","author":"GQ Daley","year":"1990","unstructured":"Daley, G.Q., Van Etten, R.A. & Baltimore, D. Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome. Science 247, 824\u2013830 (1990).","journal-title":"Science"},{"key":"BFni1701_CR9","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker, B.J. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2, 561\u2013566 (1996).","journal-title":"Nat. Med."},{"key":"BFni1701_CR10","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O'Brien","year":"2003","unstructured":"O'Brien, S.G. et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348, 994\u20131004 (2003).","journal-title":"N. Engl. J. Med."},{"key":"BFni1701_CR11","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker, B.J. et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355, 2408\u20132417 (2006).","journal-title":"N. Engl. J. Med."},{"key":"BFni1701_CR12","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1056\/NEJMoa064320","volume":"355","author":"CE Geyer","year":"2006","unstructured":"Geyer, C.E. et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355, 2733\u20132743 (2006).","journal-title":"N. Engl. J. Med."},{"key":"BFni1701_CR13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nbt1358","volume":"26","author":"MW Karaman","year":"2008","unstructured":"Karaman, M.W. et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26, 127\u2013132 (2008).","journal-title":"Nat. Biotechnol."},{"key":"BFni1701_CR14","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa025217","volume":"348","author":"J Cools","year":"2003","unstructured":"Cools, J. et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 348, 1201\u20131214 (2003).","journal-title":"N. Engl. J. Med."},{"key":"BFni1701_CR15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/ng0197-95","volume":"15","author":"MP Simon","year":"1997","unstructured":"Simon, M.P. et al. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat. Genet. 15, 95\u201398 (1997).","journal-title":"Nat. Genet."},{"key":"BFni1701_CR16","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1056\/NEJMoa052955","volume":"354","author":"SS Baroni","year":"2006","unstructured":"Baroni, S.S. et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N. Engl. J. Med. 354, 2667\u20132676 (2006).","journal-title":"N. Engl. J. Med."},{"key":"BFni1701_CR17","doi-asserted-by":"publisher","first-page":"18895","DOI":"10.1073\/pnas.0810246105","volume":"105","author":"C Louvet","year":"2008","unstructured":"Louvet, C. et al. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc. Natl. Acad. Sci. USA 105, 18895\u201318900 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFni1701_CR18","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre, M.E. et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876\u2013880 (2001).","journal-title":"Science"},{"key":"BFni1701_CR19","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1038\/nsmb.1486","volume":"15","author":"M Azam","year":"2008","unstructured":"Azam, M., Seeliger, M.A., Gray, N.S., Kuriyan, J. & Daley, G.Q. Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat. Struct. Mol. Biol. 15, 1109\u20131118 (2008).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"BFni1701_CR20","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/372739a0","volume":"372","author":"JC Lee","year":"1994","unstructured":"Lee, J.C. et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372, 739\u2013746 (1994).","journal-title":"Nature"},{"key":"BFni1701_CR21","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/377065a0","volume":"377","author":"P Macchi","year":"1995","unstructured":"Macchi, P. et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 377, 65\u201368 (1995).","journal-title":"Nature"},{"key":"BFni1701_CR22","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1126\/science.270.5237.797","volume":"270","author":"SM Russell","year":"1995","unstructured":"Russell, S.M. et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 270, 797\u2013800 (1995).","journal-title":"Science"},{"key":"BFni1701_CR23","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1074-7613(00)00054-6","volume":"13","author":"M Karaghiosoff","year":"2000","unstructured":"Karaghiosoff, M. et al. Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity 13, 549\u2013560 (2000).","journal-title":"Immunity"},{"key":"BFni1701_CR24","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.immuni.2006.09.009","volume":"25","author":"Y Minegishi","year":"2006","unstructured":"Minegishi, Y. et al. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 25, 745\u2013755 (2006).","journal-title":"Immunity"},{"key":"BFni1701_CR25","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1126\/science.1135245","volume":"314","author":"RH Duerr","year":"2006","unstructured":"Duerr, R.H. et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314, 1461\u20131463 (2006).","journal-title":"Science"},{"key":"BFni1701_CR26","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1038\/ng.2007.17","volume":"39","author":"PR Burton","year":"2007","unstructured":"Burton, P.R. et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat. Genet. 39, 1329\u20131337 (2007).","journal-title":"Nat. Genet."},{"key":"BFni1701_CR27","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","volume":"371","author":"CL Leonardi","year":"2008","unstructured":"Leonardi, C.L. et al. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371, 1665\u20131674 (2008).","journal-title":"Lancet"},{"key":"BFni1701_CR28","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1126\/science.1087061","volume":"302","author":"PS Changelian","year":"2003","unstructured":"Changelian, P.S. et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302, 875\u2013878 (2003).","journal-title":"Science"},{"key":"BFni1701_CR29","first-page":"4116","volume":"54","author":"JM Kremer","year":"2006","unstructured":"Kremer, J.M. et al. A randomized, double-blind placebo-controlled trial of 3 dose levels of CP-690,550 versus placebo in the treatment of active rheumatoid arthritis. Arthritis Rheum. 54, 4116 (2006).","journal-title":"Arthritis Rheum."},{"key":"BFni1701_CR30","first-page":"S297","volume":"58","author":"B Wilkinson","year":"2008","unstructured":"Wilkinson, B., Chow, V., LaBadie, R., Zwillich, S.H. & Cohen, S. Co-administration of an oral JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis. Arthritis Rheum. 58, S297 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFni1701_CR31","first-page":"S87","volume":"6","author":"G Chan","year":"2006","unstructured":"Chan, G., Cunshan, W., Boy, M., Chow, V. & Herron, J. Dose-dependent reduction in psoriasis severity as evidence of immunosuppressive activity of an oral Jak3 inhibitor in humans. Am. J. Transplant. 6, S87 (2006).","journal-title":"Am. J. Transplant."},{"key":"BFni1701_CR32","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1111\/j.1600-6143.2008.02307.x","volume":"8","author":"E van Gurp","year":"2008","unstructured":"van Gurp, E. et al. Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics. Am. J. Transplant. 8, 1711\u20131718 (2008).","journal-title":"Am. J. Transplant."},{"key":"BFni1701_CR33","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0092-8674(00)81167-8","volume":"93","author":"E Parganas","year":"1998","unstructured":"Parganas, E. et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 93, 385\u2013395 (1998).","journal-title":"Cell"},{"key":"BFni1701_CR34","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter, E.J. et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365, 1054\u20131061 (2005).","journal-title":"Lancet"},{"key":"BFni1701_CR35","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James, C. et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434, 1144\u20131148 (2005).","journal-title":"Nature"},{"key":"BFni1701_CR36","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics, R. et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352, 1779\u20131790 (2005).","journal-title":"N. Engl. J. Med."},{"key":"BFni1701_CR37","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine, R.L. et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7, 387\u2013397 (2005).","journal-title":"Cancer Cell"},{"key":"BFni1701_CR38","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.ccr.2008.02.017","volume":"13","author":"I Geron","year":"2008","unstructured":"Geron, I. et al. Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell 13, 321\u2013330 (2008).","journal-title":"Cancer Cell"},{"key":"BFni1701_CR39","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ccr.2008.02.009","volume":"13","author":"G Wernig","year":"2008","unstructured":"Wernig, G. et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 13, 311\u2013320 (2008).","journal-title":"Cancer Cell"},{"key":"BFni1701_CR40","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1111\/j.1349-7006.2008.00817.x","volume":"99","author":"T Manshouri","year":"2008","unstructured":"Manshouri, T. et al. The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation. Cancer Sci. 99, 1265\u20131273 (2008).","journal-title":"Cancer Sci."},{"key":"BFni1701_CR41","first-page":"S431","volume":"58","author":"W Williams","year":"2008","unstructured":"Williams, W. et al. A randomized placebo-controlled study of INCB018424, a selective Janus kinase1&2 (JAK1&2) inhibitor in rheumatoid arthritis (RA). Arthritis Rheum. 58, S431 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFni1701_CR42","doi-asserted-by":"publisher","first-page":"3309","DOI":"10.1002\/art.23992","volume":"58","author":"ME Weinblatt","year":"2008","unstructured":"Weinblatt, M.E. et al. Treatment of rheumatoid arthritis with a syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum. 58, 3309\u20133318 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFni1701_CR43","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/nm.1890","volume":"14","author":"JA Engelman","year":"2008","unstructured":"Engelman, J.A. et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 14, 1351\u20131356 (2008).","journal-title":"Nat. Med."},{"key":"BFni1701_CR44","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/nchembio.117","volume":"4","author":"B Apsel","year":"2008","unstructured":"Apsel, B. et al. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat. Chem. Biol. 4, 691\u2013699 (2008).","journal-title":"Nat. Chem. Biol."}],"container-title":["Nature Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ni.1701.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ni.1701","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ni.1701.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T23:35:45Z","timestamp":1684452945000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ni.1701"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,19]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["BFni1701"],"URL":"https:\/\/doi.org\/10.1038\/ni.1701","relation":{},"ISSN":["1529-2908","1529-2916"],"issn-type":[{"value":"1529-2908","type":"print"},{"value":"1529-2916","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3,19]]}}}